Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE4TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 15, 2018

Primary Completion Date

March 27, 2020

Study Completion Date

June 10, 2020

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Nintedanib

stable dose

OTHER

Pulmonary rehabilitation program

12 weeks

Trial Locations (19)

10029

Icahn School of Medicine at Mount Sinai, New York

19456

Temple University Hospital, Oaks

21286

Pulmonary and Critical Care Associates of Baltimore, Towson

22903

University of Virginia Health System, Charlottesville

27403

Pulmonix, LLC, Greensboro

33125

Miami VA Healthcare System, Miami

33704

Coastal Pulmonary & Crit Care, St. Petersburg

35294

University of Alabama at Birmingham, Birmingham

37232

Vanderbilt University Medical Center, Nashville

46360

The LaPorte County Institute for Clinical Research, Michigan City

48109

University of Michigan Health System, Ann Arbor

53226

Froedtert and The Medical College of Wisconsin, Milwaukee

59101

St. Vincent Physicians Sleep and Respiratory Center, Billings

59901

Glacier View Research Institute, Kalispell

75246

Baylor University Medical Center, Dallas

92354

Loma Linda University Medical Center, Loma Linda

99204

Providence Sacred Heart Medical Center and Children's Hospital, Spokane

06810

Western Connecticut Medical Group, Danbury

75069-1769

Metroplex Pul and Sleep Ctr, McKinney

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT03717012 - Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter